Does nonmetastatic castration-resistant prostate cancer still exist?

被引：0
|
作者：
Celestia S. Higano
机构：
[1] University of Washington,Division of Medical Oncology, Department of Medicine
[2] Fred Hutchinson Cancer Research Center,undefined
[3] Seattle Cancer Care Alliance,undefined
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
After almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered.
引用
收藏
页码：350 / 351
页数：1
相关论文
共 50 条
  • [41] IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Shore, Neal
    Stenzl, Arnulf
    Pieczonka, Christopher
    Klaassen, Zachary
    Aronson, William
    Karsh, Lawrence
    Ryan, Charles
    Miskic, Marina
    Srinivasan, Shankar
    Mohamed, Ateesha
    Verholen, Frank
    JOURNAL OF UROLOGY, 2021, 206 : E586 - E587
  • [42] Salvage Therapy With Bicalutamide 150 mg in Nonmetastatic Castration-resistant Prostate Cancer
    Lodde, Michele
    Lacombe, Louis
    Fradet, Yves
    UROLOGY, 2010, 76 (05) : 1189 - 1193
  • [43] Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
    Esther, John
    Maughan, Benjamin L.
    Anderson, Neysi
    Agarwal, Neeraj
    Hahn, Andrew W.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (02)
  • [44] Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 201 (01): : 31 - 31
  • [45] Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer
    Bhindi, Bimal
    Karnes, R. Jeffrey
    EUROPEAN UROLOGY, 2018, 74 (04) : 534 - 535
  • [46] Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.
    Small, Eric Jay
    Saad, Fred
    Zheng, Ying
    Pan, Feng
    Mehra, Maneesha
    Lawson, Joe
    Hadaschik, Boris A.
    Uemura, Hiroji
    Lee, Ji Youl
    Mainwaring, Paul N.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Treatment of Nonmetastatic Castration Resistant Prostate Cancer
    Luo, Jia
    Beer, Tomasz M.
    Graff, Julie N.
    ONCOLOGY-NEW YORK, 2016, 30 (04): : 336 - 344
  • [48] Prostate-specific antigen response with enzalutamide in nonmetastatic castration-resistant prostate cancer: PROSPER
    von Bueren, Moritz
    Sternberg, N.
    Fizazi, Karim
    Saad, Fred
    Rathenborg, Per
    Shore, Neal D.
    Demirhan, Eren
    Modelska, Katharina
    De Phung
    Krivoshik, Andrew
    Hussain, Maha
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 17S
  • [49] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [50] Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
    Cattrini, Carlo
    Caffo, Orazio
    De Giorgi, Ugo
    Mennitto, Alessia
    Gennari, Alessandra
    Olmos, David
    Castro, Elena
    CANCERS, 2022, 14 (07)
12345